In today’s briefing:
- [IO Technicals 2025/32] Bullish Momentum Builds
- BoAn Biotechnology (6955 HK): Profitable Operation & Pipeline Progress Make the Placement Attractive
- BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision
- Hong Kong Single Stock Options Weekly (Aug 04–08): HSI Rebounds, Single Stock Option Activity Fades
[IO Technicals 2025/32] Bullish Momentum Builds
- China’s July steel exports hit highest year-to-date level since 1990, and S&P affirms A+ rating despite property and trade challenges.
- Managed money participants turned net long in futures after prolonged bearishness, adding positions as prices neared the $100/ton mark.
- Despite a recent death cross, prices remain firm above short-term MA, nearing bullish crossover, with Bollinger Bands signalling resilience and upside potential.
BoAn Biotechnology (6955 HK): Profitable Operation & Pipeline Progress Make the Placement Attractive
- Shandong BoAn Biotechnology (6955 HK) is placing 48M shares, representing 7.7% of the total number of issued shares post placement. Placement price is HK$16.42, 9% discount to last undisturbed price.
- The expected net proceeds of ~HK$780M will be used for funding R&D of innovative product candidates and commercialization of marketed and upcoming products.
- This is the second placement of the company this year. In June, Boan Biotech raised ~HK$396M through placing 26.7M shares. The company is not expected to raise fund anytime soon.
BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision
- BeiGene (6160 HK) reported 2Q25 revenues of $1.3B, up 42% YoY (1H25 Revenue: $2.4B, up 45%), driven primarily by growth in Brukinsa sales in the U.S. and Europe.
- In 2Q25, U.S. sale of Brukinsa was $684M, up 43% YoY. For three consecutive quarters now, Brukinsa outpaced its closest competitor Calquence which reported US revenue of $583M in 2Q25.
- BeiGene now expects 2025 revenue to be in the range of $5.0–5.3B (up 29–39% YoY) compared to the previous revenue guidance of $4.9–5.3B.
Hong Kong Single Stock Options Weekly (Aug 04–08): HSI Rebounds, Single Stock Option Activity Fades
- Hang Seng Index back in the green with broad based gains across optionable names.
- Single stock option volumes were very lackluster and Call enthusiasm continues to be muted.
- Full slate of earnings announcements on tap for the upcoming week.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
